Skylar Jeremias

December 09, 2022

Here are the top 5 biosimilar articles for the week of December 5, 2022.

December 08, 2022

Following their initial European launch of the drug, Alvotech and STADA Arzneimittel launch their adalimumab biosimilar referencing Humira in 7 more European countries: Belgium, Bulgaria, Croatia, the Czech Republic, Latvia, Romania, and Slovenia.

December 07, 2022

John Gabrielson, senior vice president at JSR Life Sciences and head of Similis Bio, talked about the challenges associated with launching a business venture like Similis Bio and how Similis Bio's business model differs from other biosimilar developers and their spin-offs.

December 06, 2022

Prime Therapeutics has officially acquired Magellan Rx Management, a popular pharmacy benefit manager (PBM) in the specialty pharmacy space. The acquisition was announced in May 2022 and includes the acquisition of Magellan Rx’s specialty, PBM, and government pharmaceutical and Medicaid business segments.

December 05, 2022

The Accreditation Council for Medical Affairs (ACMA) is launching a new program for health care professionals to become Board Certified Biologics and Biosimilars Specialists.

December 04, 2022

On this episode of Not So Different, we recap some of the big regulatory news to come out of November, including some progress for insulin biosimilars, the European approval of another ranibizumab biosimilar, and the congressional introduction of a US Senate bill that is seeking to nix switching study requirements for interchangeability.

December 02, 2022

Here are the top 5 biosimilar articles for the week of November 28, 2022.

December 01, 2022

In November, several global agencies progressed insulin biosimilars, the European Union approved another ranibizumab biosimilar, and a US Senate bill to rid switching study requirements for interchangeability was introduced to Congress.

November 30, 2022

Capstone has announced that its human insulin biosimilar received positive opinions from the European Medicines Agency and Health Canada, signaling approvals may be on the horizon, and the acquisition of Viatris’ biosimilars portfolio by Biocon Biologics is officially complete.

November 29, 2022

After receiving FDA approval in February 2022, Amneal Pharmaeuticals and Kashiv Biosciences launched Releuko (filgrastim-ayow) on the US market, making it the fourth biosimilar referencing Neupogen to be commercially available to Americans.